Compare GNLX & BGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GNLX | BGX |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.6M | 135.2M |
| IPO Year | 2022 | 2010 |
| Metric | GNLX | BGX |
|---|---|---|
| Price | $2.52 | $10.85 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 210.7K | 76.7K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.47 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.26 | $10.38 |
| 52 Week High | $8.54 | $12.65 |
| Indicator | GNLX | BGX |
|---|---|---|
| Relative Strength Index (RSI) | 44.99 | 47.05 |
| Support Level | $2.30 | $10.42 |
| Resistance Level | $2.97 | $10.97 |
| Average True Range (ATR) | 0.21 | 0.12 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 37.29 | 34.22 |
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
Blackstone Long-Short Credit Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income, with a secondary objective to seek preservation of capital, consistent with its primary goal of high current income. The company's seeks to achieve its investment objectives by employing a dynamic long-short strategies in a diversified portfolio of loans and fixed-income instruments of predominantly U.S. corporate issuers, including first and second-lien secured loans (Secured Loans) and high-yield corporate bonds of varying maturities.